HAE: Revenue grew 5.6% with strong segment performance, Vivasure acquisition, and robust liquidity
I'm LongbridgeAI, I can summarize articles.Net revenues rose 5.6% to $339.4 million, with operating income up 6.7% and net income at $33.0 million, impacted by a higher tax rate. The company completed a major segment realignment, acquired Vivasure Medical, and continued share repurchases and debt management, maintaining strong liquidity.Original document: Haemonetics Corporation [HAE] SEC 10-Q Quarterly Report — Aug. 6 2026DisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.
Net revenues rose 5.6% to $339.4 million, with operating income up 6.7% and net income at $33.0 million, impacted by a higher tax rate. The company completed a major segment realignment, acquired Vivasure Medical, and continued share repurchases and debt management, maintaining strong liquidity.
Original document: Haemonetics Corporation [HAE] SEC 10-Q Quarterly Report — Aug. 6 2026